ÂÜÀòÂÒÂ×

Leonid Gaidukov, PhD has extensive work experience in the field of molecular biology and synthetic biology. Leonid has held various roles with different companies and institutions.

Starting in 1999, Gaidukov worked as an MSc student in Biotechnology at the Hebrew University of Jerusalem. Here, they studied antimicrobial peptides and their structure-activity relationships.

In 2002, Gaidukov became a PhD student at the Weizmann Institute of Science. Leonid'sresearch focused on directed evolution and mechanistic studies of HDL-associated enzymes. Leonid also conducted collaborative work with other researchers to generate recombinant PON1 variants.

From 2014 to 2016, Gaidukov worked as a research scientist in the MIT-Pfizer collaboration.

From 2009 to 2014, Gaidukov held two positions at the Massachusetts Institute of Technology (MIT). As a post-doctoral associate in the Biology Department, they conducted research on the structure and function of the HDL receptor SR-BI. As a research scientist in the Pfizer-MIT Partnership in Synthetic Biology, they developed synthetic biology strategies for large DNA integration into mammalian cell genomes.

Gaidukov then joined Codiak BioSciences in 2018 as a Scientist II in Molecular Biology.

In 2021, Gaidukov moved to Beam Therapeutics, where they worked as a Senior Scientist in Synthetic Biology. Leonid focused on the discovery and development of gene editing technologies for targeted integration.

Currently, Gaidukov is a Senior Scientist at March Therapeutics, Inc. Leonid'srole involves the development of novel programmable gene editing systems in disease-relevant contexts.

Overall, Leonid Gaidukov, PhD has had a diverse and successful career in research and development in molecular and synthetic biology.

Leonid Gaidukov, PhD, pursued a Bachelor's degree in Biology, General from The Hebrew University of Jerusalem from 1995 to 1999. Leonid then went on to earn a Master of Science (MS) in Biotechnology from the same institution, studying from 1999 to 2001. Subsequently, Leonid attended the Weizmann Institute of Science from 2001 to 2009, where they obtained a Doctor of Philosophy (PhD) in Biological Chemistry. Leonid furthered their education at the prestigious Massachusetts Institute of Technology, pursuing a Post-doctorate in Biochemistry and Molecular Biology from 2009 to 2014.